Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Opioid coprescribing

Prescribing alerts could cut opioid and benzodiazepine coprescribing

Researchers have found that an electronic alert system significantly reduced coprescribing in patients with sleep apnoea and people at risk of suicide.

Benzodiazepine, anxiolytic pills

Source: Garo / Phanie / Science Photo Library

The medical record alert system decreased coprescribing of opioids and benzodiazepines by 38.5% in people with sleep apnoea and by 61.5% in people at risk of suicide, compared with coprescribing prior to the alert launch

An electronic medical record alert system could potentially reduce coprescribing and related overdose deaths, researchers have found[1].

In a 12-month study published in Medical Care (1 February 2018), the alert system, which notifies the prescribers of opioid and benzodiazepine coprescribing in people with high-risk conditions, such as substance abuse and suicide risk, was activated for 1,332 patients.

The researchers found that coprescribing decreased significantly by 38.5% in people with sleep apnoea and by 61.5% in people at risk of suicide, compared to coprescribing prior to the alert launch.

However, among people who had been receiving long-term coprescribed benzodiazepines and opioids, coprescribing remained at 69% six months after the alert.

The researchers said: “Medication alerts hold promise as a means of reducing opioid and benzodiazepine coprescribing among certain high-risk groups”. However, they added that further research should explore whether this is more effective when used in combination with other interventions.

“Given current trends in overdose deaths involving opioids and benzodiazepines, tools to assist prescribers in reducing coprescribing are needed.”

Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20204910

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Benzodiazepine, anxiolytic pills

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.